State of New Jersey Common Pension Fund D Acquires 22,063 Shares of Envista Holdings Co. (NYSE:NVST)

State of New Jersey Common Pension Fund D grew its stake in Envista Holdings Co. (NYSE:NVST) by 26.1% during the 4th quarter, HoldingsChannel reports. The firm owned 106,535 shares of the company’s stock after acquiring an additional 22,063 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Envista were worth $2,563,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Foundry Partners LLC bought a new position in Envista during the 4th quarter valued at about $3,571,000. Raymond James & Associates boosted its holdings in shares of Envista by 820.6% in the 4th quarter. Raymond James & Associates now owns 408,218 shares of the company’s stock worth $9,822,000 after acquiring an additional 363,875 shares in the last quarter. River Road Asset Management LLC bought a new stake in Envista during the 4th quarter worth approximately $54,931,000. DAVENPORT & Co LLC acquired a new stake in Envista during the 4th quarter valued at $13,233,000. Finally, Blueshift Asset Management LLC raised its position in Envista by 168.7% in the 3rd quarter. Blueshift Asset Management LLC now owns 41,524 shares of the company’s stock valued at $1,158,000 after purchasing an additional 26,073 shares during the last quarter.

Envista Trading Up 0.4 %

NYSE:NVST opened at $19.75 on Thursday. Envista Holdings Co. has a 1-year low of $18.95 and a 1-year high of $38.43. The business’s 50-day moving average price is $20.80 and its two-hundred day moving average price is $22.59. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.23 and a quick ratio of 1.90.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, February 7th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.04). Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The firm had revenue of $645.60 million for the quarter, compared to the consensus estimate of $638.37 million. During the same period in the previous year, the business earned $0.52 EPS. The firm’s revenue was down 2.3% compared to the same quarter last year. As a group, research analysts expect that Envista Holdings Co. will post 1.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NVST. SVB Leerink initiated coverage on Envista in a report on Monday, February 26th. They set an “underperform” rating and a $19.00 target price on the stock. TheStreet cut shares of Envista from a “c” rating to a “d+” rating in a research report on Wednesday, February 7th. William Blair lowered shares of Envista from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 8th. Leerink Partnrs restated an “underperform” rating on shares of Envista in a research report on Monday, February 26th. Finally, UBS Group assumed coverage on Envista in a report on Friday, January 5th. They set a “neutral” rating and a $26.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $27.90.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.